drugset
drugset / Trial / NCT03992443

Efficacy and Safety of CUSA-081 in the Restoration of Dysfunctional Central Venous Access Device (CVAD) Functionality

NCT03992443 ↗

Phase 3 Withdrawn Chiesi Farmaceutici S.p.A.
NaSingle-groupOpen-labelTreatment

Summary

Study to evaluate the efficacy and safety of CUSA-081 in the restoration of central venous access device (CVAD) functionality in participants 12 years and older.

Timeline

Start
2022-02-28
Primary completion
2022-03-18
Completion
2022-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject reteplase Protein / enzyme biologic 0.7 mg Other

Indications

No indication recorded.